ArticleIDCases2026
Identification of occult hepatitis B infection despite high anti-HBs in a hemodialysis patient during pretransplant evaluation.
Article in IDCases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Occult hepatitis B virus infection is characterized by detectable hepatitis B virus DNA in individuals who test negative for hepatitis B surface antigen (HBsAg). In patients awaiting kidney transplantation, unrecognized occult hepatitis B virus infection may increase the risk of viral reactivation following immunosuppressive therapy. However, hepatitis B screening in many clinical settings still relies primarily on HBsAg and anti- HBs testing, which may fail to identify occult infection. We report the case of a 39-year- old woman with end-stage renal disease receiving maintenance hemodialysis who was evaluated for kidney transplantation. Routine serological screening showed negative HBsAg and a high anti-HBs titer (292.3 IU/L), suggesting resolved hepatitis B virus infection. However, further evaluation revealed positive total anti-HBc and detectable serum hepatitis B virus DNA with a viral load of 9.54 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.